Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.38 |
| ▸ | ABAT | P80404 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 4/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD5 | P21918 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10649625 | 0.83 | HDAC1 (0.52) | HDAC1HDAC6HCAR2 | |
| SCHEMBL9419852 | 0.82 | HDAC6 (0.57) | HDAC1HDAC6HCAR2CHEK1 | |
| SCHEMBL4082020 | 0.79 | CDK8 (0.48) | HDAC1HDAC6CYP2A6ALDH1A1CHEK1 | |
| SCHEMBL9468087 | 0.75 | DRD1 (0.44) | CYP2A6ALDH1A1HSD17B10DRD1DRD2 | |
| SCHEMBL380666 | 0.74 | — | — | |
| SCHEMBL24409228 | 0.73 | KDR (0.43) | CYP2A6ALDH1A1CHEK1KDM4E | |
| SCHEMBL30630850 | 0.73 | KDR (0.43) | CYP2A6ALDH1A1CHEK1KDM4E | |
| SCHEMBL27462334 | 0.73 | HDAC1 (0.50) | HDAC1HDAC6ALDH1A1HSD17B10HCAR2 | |
| Hydrochloric Acid SCHEMBL3824245 | 0.72 | HDAC6 (0.48) | HDAC1HDAC6HCAR2KDM4E | |
| SCHEMBL80142 | 0.72 | HDAC1 (0.48) | HDAC1HDAC6ALDH1A1HCAR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106866658-B | 1H-pyrrolo [2,3-b ] pyridine derivatives and their use as kinase inhibitors | 沃纳利斯(R&D)有限公司 | 2021-04-27 | — | — | CN | disclosed |
| CN-111484493-A | 1H-pyrrolo [2,3-b ] pyridine derivatives and their use as kinase inhibitors | 沃纳利斯(R&D)有限公司 | 2020-08-04 | — | — | CN | disclosed |
| CN-107011341-A | 1H-pyrrolo [2,3-b ] pyridine derivatives and their use as kinase inhibitors | 沃纳利斯(R&D)有限公司 | 2017-08-04 | — | — | CN | disclosed |
| CN-106866658-A | 1H-pyrrolo [2,3-b ] pyridine derivatives and their use as kinase inhibitors | 沃纳利斯(R&D)有限公司 | 2017-06-20 | — | — | CN | disclosed |
| US-8247571-B2 | Pyridinium and thiazolium conjugates including polyethylene glycols and methods of using the same | MYCOSOL, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20110053987-A1 | PYRIDINIUM AND THIAZOLIUM CONJUGATES INCLUDING POLYETHYLENE GLYCOLS AND METHODS OF USING THE SAME | MYCOSOL, INC. | 2011-03-03 | — | — | US | disclosed |
| WO-2007056556-A2 | POLYETHYLENE GLYCOL CONJUGATES OF PYRIDINIUM AND THIAZOLIUM COMPOUNDS AND METHODS OF USING THE SAME | MYCOSOL, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053987-A1 | PYRIDINIUM AND THIAZOLIUM CONJUGATES INCLUDING POLYETHYLENE GLYCOLS AND METHODS OF USING THE SAME | PLPBP, PTPMT1, PNPO | HDAC1 1920/4885HDAC6 1655/4885CYP2A6 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.